Literature DB >> 22410444

Incidence of new-onset seizures in mild to moderate Alzheimer disease.

Michael C Irizarry1, Shelia Jin, Feng He, Jennifer A Emond, Rema Raman, Ronald G Thomas, Mary Sano, Joseph F Quinn, Pierre N Tariot, Douglas R Galasko, Lianna S Ishihara, John G Weil, Paul S Aisen.   

Abstract

OBJECTIVE: To estimate the incidence rate and predictors of seizures in patients with mild to moderate Alzheimer disease (AD).
DESIGN: Cohort study of patients with mild to moderate AD in clinical trials. Risk factors for potential seizures were evaluated by stratified descriptive statistics and univariable and multivariable Cox proportional hazards regressions.
SETTING: Pooled patient-level data from 10 Alzheimer Disease Cooperative Study clinical trials in mild to moderate AD from 1995 to 2010. PATIENTS: Three thousand seventy-eight subjects randomized to the treatment or placebo arms of 10 AD clinical trials. Screening Mini-Mental State Examination scores ranged between 10 and 28.
RESULTS: Eighteen seizures were reported in 3078 randomized subjects, with an incidence rate of 484 per 100 000 person-years (95% CI, 287-764). Statistically significant independent risk factors for seizure were younger age (adjusted hazard ratio, 0.80; 95% CI, 0.69-0.93 per every 5 years of age), greater cognitive impairment at baseline (adjusted hazard ratio, 2.79; 95% CI, 1.06-7.33 for Mini-Mental State Examination scores <18 compared with Mini-Mental State Examination scores ≥18), and antipsychotic use at baseline (adjusted hazard ratio, 3.47; 95% CI, 1.33-9.08).
CONCLUSIONS: Seizure rates in patients with mild to moderate AD in clinical trials are similar to rates observed in longer observational cohort studies, but they are greater than expected in the general elderly population. Younger age, greater degree of cognitive impairment, and history of antipsychotic use were independent risk factors for new-onset seizures in AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410444      PMCID: PMC3622046          DOI: 10.1001/archneurol.2011.830

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  17 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Seizures and myoclonus in patients with Alzheimer's disease.

Authors:  W A Hauser; M L Morris; L L Heston; V E Anderson
Journal:  Neurology       Date:  1986-09       Impact factor: 9.910

Review 3.  Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003.

Authors:  Susan A Ropacki; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2005-11       Impact factor: 18.112

4.  Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

Authors:  R A Mulnard; C W Cotman; C Kawas; C H van Dyck; M Sano; R Doody; E Koss; E Pfeiffer; S Jin; A Gamst; M Grundman; R Thomas; L J Thal
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

Review 5.  Antipsychotic medication and seizures: a review.

Authors:  Dawson Hedges; Kreg Jeppson; Paul Whitehead
Journal:  Drugs Today (Barc)       Date:  2003-07       Impact factor: 2.245

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

Authors:  Paul S Aisen; Kimberly A Schafer; Michael Grundman; Eric Pfeiffer; Mary Sano; Kenneth L Davis; Martin R Farlow; Shelia Jin; Ronald G Thomas; Leon J Thal
Journal:  JAMA       Date:  2003-06-04       Impact factor: 56.272

8.  Advanced Alzheimer's disease is a risk factor for late-onset seizures.

Authors:  M F Romanelli; J C Morris; K Ashkin; L A Coben
Journal:  Arch Neurol       Date:  1990-08

9.  Dementia and adult-onset unprovoked seizures.

Authors:  D C Hesdorffer; W A Hauser; J F Annegers; E Kokmen; W A Rocca
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

10.  Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984.

Authors:  W A Hauser; J F Annegers; L T Kurland
Journal:  Epilepsia       Date:  1993 May-Jun       Impact factor: 5.864

View more
  37 in total

1.  Seizures and epileptiform activity in the early stages of Alzheimer disease.

Authors:  Keith A Vossel; Alexander J Beagle; Gil D Rabinovici; Huidy Shu; Suzee E Lee; Georges Naasan; Manu Hegde; Susannah B Cornes; Maya L Henry; Alexandra B Nelson; William W Seeley; Michael D Geschwind; Maria L Gorno-Tempini; Tina Shih; Heidi E Kirsch; Paul A Garcia; Bruce L Miller; Lennart Mucke
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

2.  Seizures and epileptiform activity in early Alzheimer disease: how hard should we be looking?

Authors:  David Spencer
Journal:  Epilepsy Curr       Date:  2014-03       Impact factor: 7.500

Review 3.  Network abnormalities and interneuron dysfunction in Alzheimer disease.

Authors:  Jorge J Palop; Lennart Mucke
Journal:  Nat Rev Neurosci       Date:  2016-11-10       Impact factor: 34.870

4.  Corticothalamic network dysfunction and Alzheimer's disease.

Authors:  Rohan Jagirdar; Jeannie Chin
Journal:  Brain Res       Date:  2017-09-15       Impact factor: 3.252

5.  Neurodegenerative disease is associated with increased incidence of epilepsy: a population based study of older adults.

Authors:  Leah J Blank; Emily K Acton; Dylan Thibault; Allison W Willis
Journal:  Age Ageing       Date:  2021-01-08       Impact factor: 10.668

6.  Seizures in setting of dementia.

Authors:  Kartik Sivaraaman; Vimala S Vajjala
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 7.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Seizures in Alzheimer disease: clinical and epidemiological data.

Authors:  Dionysios Pandis; Nikolaos Scarmeas
Journal:  Epilepsy Curr       Date:  2012-09       Impact factor: 7.500

9.  Association between white matter hyperintensities, cortical volumes, and late-onset epilepsy.

Authors:  Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Anna M Kucharska-Newton; Juebin Huang; Clifford R Jack; Rebecca F Gottesman
Journal:  Neurology       Date:  2019-01-25       Impact factor: 9.910

Review 10.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.

Authors:  Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom
Journal:  Nat Rev Neurosci       Date:  2015-08-05       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.